English
简体中文
Total: £ 56.28
Published Date: 2025-11-03 | Pages: 141 | Tables: 138 | New Technology
The global Normothermic Perfusion of Isolated Organs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Organ Transplant Specialist Hospitals accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Normothermic Perfusion of Isolated Organs leading manufacturers including TransMedics, Lung Bioengineering, OrganOx, XVIVO, TNO, UHN, SCREEN, Bridge to Life, Organ Recovery Systems, Institut Georges Lopez, etc., dominate supply; the top five capture approximately % of global revenue, with TransMedics leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Normothermic Perfusion of Isolated Organs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
TransMedics
Lung Bioengineering
OrganOx
XVIVO
TNO
UHN
SCREEN
Bridge to Life
Organ Recovery Systems
Institut Georges Lopez
Ebers
Penn Medicine
Johns Hopkins Medicine
Segment by Type
Heart Perfusion
Liver Perfusion
Kidney Perfusion
Lung Perfusion
Segment by Application
Organ Transplant Specialist Hospitals
Organ Banks
Pharmaceutical Research Organizations
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Normothermic Perfusion of Isolated Organs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Normothermic Perfusion of Isolated Organs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Normothermic Perfusion of Isolated Organs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Heart Perfusion
1.2.3 Liver Perfusion
1.2.4 Kidney Perfusion
1.2.5 Lung Perfusion
1.3 Market Segmentation by Application
1.3.1 Global Normothermic Perfusion of Isolated Organs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Organ Transplant Specialist Hospitals
1.3.3 Organ Banks
1.3.4 Pharmaceutical Research Organizations
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Normothermic Perfusion of Isolated Organs Revenue Estimates and Forecasts 2020-2031
2.2 Global Normothermic Perfusion of Isolated Organs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Normothermic Perfusion of Isolated Organs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Normothermic Perfusion of Isolated Organs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Heart Perfusion Market Size by Players
3.3.2 Liver Perfusion Market Size by Players
3.3.3 Kidney Perfusion Market Size by Players
3.3.4 Lung Perfusion Market Size by Players
3.4 Global Normothermic Perfusion of Isolated Organs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Normothermic Perfusion of Isolated Organs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Normothermic Perfusion of Isolated Organs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Normothermic Perfusion of Isolated Organs Market Size by Type (2020-2031)
6.4 North America Normothermic Perfusion of Isolated Organs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Normothermic Perfusion of Isolated Organs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Normothermic Perfusion of Isolated Organs Market Size by Type (2020-2031)
7.4 Europe Normothermic Perfusion of Isolated Organs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Normothermic Perfusion of Isolated Organs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Normothermic Perfusion of Isolated Organs Market Size by Type (2020-2031)
8.4 Asia-Pacific Normothermic Perfusion of Isolated Organs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Normothermic Perfusion of Isolated Organs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Normothermic Perfusion of Isolated Organs Market Size by Type (2020-2031)
9.4 Central and South America Normothermic Perfusion of Isolated Organs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Normothermic Perfusion of Isolated Organs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Normothermic Perfusion of Isolated Organs Market Size by Type (2020-2031)
10.4 Middle East and Africa Normothermic Perfusion of Isolated Organs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Normothermic Perfusion of Isolated Organs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 TransMedics
11.1.1 TransMedics Corporation Information
11.1.2 TransMedics Business Overview
11.1.3 TransMedics Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.1.4 TransMedics Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.1.5 TransMedics Normothermic Perfusion of Isolated Organs Revenue by Product in 2024
11.1.6 TransMedics Normothermic Perfusion of Isolated Organs Revenue by Application in 2024
11.1.7 TransMedics Normothermic Perfusion of Isolated Organs Revenue by Geographic Area in 2024
11.1.8 TransMedics Normothermic Perfusion of Isolated Organs SWOT Analysis
11.1.9 TransMedics Recent Developments
11.2 Lung Bioengineering
11.2.1 Lung Bioengineering Corporation Information
11.2.2 Lung Bioengineering Business Overview
11.2.3 Lung Bioengineering Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.2.4 Lung Bioengineering Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.2.5 Lung Bioengineering Normothermic Perfusion of Isolated Organs Revenue by Product in 2024
11.2.6 Lung Bioengineering Normothermic Perfusion of Isolated Organs Revenue by Application in 2024
11.2.7 Lung Bioengineering Normothermic Perfusion of Isolated Organs Revenue by Geographic Area in 2024
11.2.8 Lung Bioengineering Normothermic Perfusion of Isolated Organs SWOT Analysis
11.2.9 Lung Bioengineering Recent Developments
11.3 OrganOx
11.3.1 OrganOx Corporation Information
11.3.2 OrganOx Business Overview
11.3.3 OrganOx Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.3.4 OrganOx Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.3.5 OrganOx Normothermic Perfusion of Isolated Organs Revenue by Product in 2024
11.3.6 OrganOx Normothermic Perfusion of Isolated Organs Revenue by Application in 2024
11.3.7 OrganOx Normothermic Perfusion of Isolated Organs Revenue by Geographic Area in 2024
11.3.8 OrganOx Normothermic Perfusion of Isolated Organs SWOT Analysis
11.3.9 OrganOx Recent Developments
11.4 XVIVO
11.4.1 XVIVO Corporation Information
11.4.2 XVIVO Business Overview
11.4.3 XVIVO Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.4.4 XVIVO Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.4.5 XVIVO Normothermic Perfusion of Isolated Organs Revenue by Product in 2024
11.4.6 XVIVO Normothermic Perfusion of Isolated Organs Revenue by Application in 2024
11.4.7 XVIVO Normothermic Perfusion of Isolated Organs Revenue by Geographic Area in 2024
11.4.8 XVIVO Normothermic Perfusion of Isolated Organs SWOT Analysis
11.4.9 XVIVO Recent Developments
11.5 TNO
11.5.1 TNO Corporation Information
11.5.2 TNO Business Overview
11.5.3 TNO Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.5.4 TNO Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.5.5 TNO Normothermic Perfusion of Isolated Organs Revenue by Product in 2024
11.5.6 TNO Normothermic Perfusion of Isolated Organs Revenue by Application in 2024
11.5.7 TNO Normothermic Perfusion of Isolated Organs Revenue by Geographic Area in 2024
11.5.8 TNO Normothermic Perfusion of Isolated Organs SWOT Analysis
11.5.9 TNO Recent Developments
11.6 UHN
11.6.1 UHN Corporation Information
11.6.2 UHN Business Overview
11.6.3 UHN Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.6.4 UHN Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.6.5 UHN Recent Developments
11.7 SCREEN
11.7.1 SCREEN Corporation Information
11.7.2 SCREEN Business Overview
11.7.3 SCREEN Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.7.4 SCREEN Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.7.5 SCREEN Recent Developments
11.8 Bridge to Life
11.8.1 Bridge to Life Corporation Information
11.8.2 Bridge to Life Business Overview
11.8.3 Bridge to Life Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.8.4 Bridge to Life Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.8.5 Bridge to Life Recent Developments
11.9 Organ Recovery Systems
11.9.1 Organ Recovery Systems Corporation Information
11.9.2 Organ Recovery Systems Business Overview
11.9.3 Organ Recovery Systems Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.9.4 Organ Recovery Systems Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.9.5 Organ Recovery Systems Recent Developments
11.10 Institut Georges Lopez
11.10.1 Institut Georges Lopez Corporation Information
11.10.2 Institut Georges Lopez Business Overview
11.10.3 Institut Georges Lopez Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.10.4 Institut Georges Lopez Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Ebers
11.11.1 Ebers Corporation Information
11.11.2 Ebers Business Overview
11.11.3 Ebers Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.11.4 Ebers Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.11.5 Ebers Recent Developments
11.12 Penn Medicine
11.12.1 Penn Medicine Corporation Information
11.12.2 Penn Medicine Business Overview
11.12.3 Penn Medicine Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.12.4 Penn Medicine Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.12.5 Penn Medicine Recent Developments
11.13 Johns Hopkins Medicine
11.13.1 Johns Hopkins Medicine Corporation Information
11.13.2 Johns Hopkins Medicine Business Overview
11.13.3 Johns Hopkins Medicine Normothermic Perfusion of Isolated Organs Product Features and Attributes
11.13.4 Johns Hopkins Medicine Normothermic Perfusion of Isolated Organs Revenue and Gross Margin (2020-2025)
11.13.5 Johns Hopkins Medicine Recent Developments
12 Normothermic Perfusion of Isolated OrgansIndustry Chain Analysis
12.1 Normothermic Perfusion of Isolated Organs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Normothermic Perfusion of Isolated Organs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Normothermic Perfusion of Isolated Organs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Normothermic Perfusion of Isolated Organs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Normothermic Perfusion of Isolated Organs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Normothermic Perfusion of Isolated Organs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Normothermic Perfusion of Isolated Organs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Normothermic Perfusion of Isolated Organs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Normothermic Perfusion of Isolated Organs Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Normothermic Perfusion of Isolated Organs Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Normothermic Perfusion of Isolated Organs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Normothermic Perfusion of Isolated Organs as of 2024)
Table 11. Global Normothermic Perfusion of Isolated Organs Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Normothermic Perfusion of Isolated Organs Companies Headquarters
Table 13. Global Normothermic Perfusion of Isolated Organs Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Normothermic Perfusion of Isolated Organs Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Normothermic Perfusion of Isolated Organs Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Normothermic Perfusion of Isolated Organs Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Normothermic Perfusion of Isolated Organs Revenue by Application (2026-2031) & (US$ Million)
Table 21. Normothermic Perfusion of Isolated Organs High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Normothermic Perfusion of Isolated Organs Growth Accelerators and Market Barriers
Table 25. North America Normothermic Perfusion of Isolated Organs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Normothermic Perfusion of Isolated Organs Growth Accelerators and Market Barriers
Table 27. Europe Normothermic Perfusion of Isolated Organs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Normothermic Perfusion of Isolated Organs Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Normothermic Perfusion of Isolated Organs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Normothermic Perfusion of Isolated Organs Investment Opportunities and Key Challenges
Table 31. Central and South America Normothermic Perfusion of Isolated Organs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Normothermic Perfusion of Isolated Organs Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Normothermic Perfusion of Isolated Organs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. TransMedics Corporation Information
Table 35. TransMedics Description and Major Businesses
Table 36. TransMedics Product Features and Attributes
Table 37. TransMedics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. TransMedics Revenue Proportion by Product in 2024
Table 39. TransMedics Revenue Proportion by Application in 2024
Table 40. TransMedics Revenue Proportion by Geographic Area in 2024
Table 41. TransMedics Normothermic Perfusion of Isolated Organs SWOT Analysis
Table 42. TransMedics Recent Developments
Table 43. Lung Bioengineering Corporation Information
Table 44. Lung Bioengineering Description and Major Businesses
Table 45. Lung Bioengineering Product Features and Attributes
Table 46. Lung Bioengineering Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Lung Bioengineering Revenue Proportion by Product in 2024
Table 48. Lung Bioengineering Revenue Proportion by Application in 2024
Table 49. Lung Bioengineering Revenue Proportion by Geographic Area in 2024
Table 50. Lung Bioengineering Normothermic Perfusion of Isolated Organs SWOT Analysis
Table 51. Lung Bioengineering Recent Developments
Table 52. OrganOx Corporation Information
Table 53. OrganOx Description and Major Businesses
Table 54. OrganOx Product Features and Attributes
Table 55. OrganOx Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. OrganOx Revenue Proportion by Product in 2024
Table 57. OrganOx Revenue Proportion by Application in 2024
Table 58. OrganOx Revenue Proportion by Geographic Area in 2024
Table 59. OrganOx Normothermic Perfusion of Isolated Organs SWOT Analysis
Table 60. OrganOx Recent Developments
Table 61. XVIVO Corporation Information
Table 62. XVIVO Description and Major Businesses
Table 63. XVIVO Product Features and Attributes
Table 64. XVIVO Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. XVIVO Revenue Proportion by Product in 2024
Table 66. XVIVO Revenue Proportion by Application in 2024
Table 67. XVIVO Revenue Proportion by Geographic Area in 2024
Table 68. XVIVO Normothermic Perfusion of Isolated Organs SWOT Analysis
Table 69. XVIVO Recent Developments
Table 70. TNO Corporation Information
Table 71. TNO Description and Major Businesses
Table 72. TNO Product Features and Attributes
Table 73. TNO Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. TNO Revenue Proportion by Product in 2024
Table 75. TNO Revenue Proportion by Application in 2024
Table 76. TNO Revenue Proportion by Geographic Area in 2024
Table 77. TNO Normothermic Perfusion of Isolated Organs SWOT Analysis
Table 78. TNO Recent Developments
Table 79. UHN Corporation Information
Table 80. UHN Description and Major Businesses
Table 81. UHN Product Features and Attributes
Table 82. UHN Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. UHN Recent Developments
Table 84. SCREEN Corporation Information
Table 85. SCREEN Description and Major Businesses
Table 86. SCREEN Product Features and Attributes
Table 87. SCREEN Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. SCREEN Recent Developments
Table 89. Bridge to Life Corporation Information
Table 90. Bridge to Life Description and Major Businesses
Table 91. Bridge to Life Product Features and Attributes
Table 92. Bridge to Life Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Bridge to Life Recent Developments
Table 94. Organ Recovery Systems Corporation Information
Table 95. Organ Recovery Systems Description and Major Businesses
Table 96. Organ Recovery Systems Product Features and Attributes
Table 97. Organ Recovery Systems Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Organ Recovery Systems Recent Developments
Table 99. Institut Georges Lopez Corporation Information
Table 100. Institut Georges Lopez Description and Major Businesses
Table 101. Institut Georges Lopez Product Features and Attributes
Table 102. Institut Georges Lopez Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Institut Georges Lopez Recent Developments
Table 104. Ebers Corporation Information
Table 105. Ebers Description and Major Businesses
Table 106. Ebers Product Features and Attributes
Table 107. Ebers Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Ebers Recent Developments
Table 109. Penn Medicine Corporation Information
Table 110. Penn Medicine Description and Major Businesses
Table 111. Penn Medicine Product Features and Attributes
Table 112. Penn Medicine Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Penn Medicine Recent Developments
Table 114. Johns Hopkins Medicine Corporation Information
Table 115. Johns Hopkins Medicine Description and Major Businesses
Table 116. Johns Hopkins Medicine Product Features and Attributes
Table 117. Johns Hopkins Medicine Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Johns Hopkins Medicine Recent Developments
Table 119. Raw Materials Key Suppliers
Table 120. Distributors List
Table 121. Market Trends and Market Evolution
Table 122. Market Drivers and Opportunities
Table 123. Market Challenges, Risks, and Restraints
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Normothermic Perfusion of Isolated Organs Product Picture
Figure 2. Global Normothermic Perfusion of Isolated Organs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Heart Perfusion Product Picture
Figure 4. Liver Perfusion Product Picture
Figure 5. Kidney Perfusion Product Picture
Figure 6. Lung Perfusion Product Picture
Figure 7. Global Normothermic Perfusion of Isolated Organs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Organ Transplant Specialist Hospitals
Figure 9. Organ Banks
Figure 10. Pharmaceutical Research Organizations
Figure 11. Normothermic Perfusion of Isolated Organs Report Years Considered
Figure 12. Global Normothermic Perfusion of Isolated Organs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 14. Global Normothermic Perfusion of Isolated Organs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Normothermic Perfusion of Isolated Organs Revenue Market Share by Region (2020-2031)
Figure 16. Global Normothermic Perfusion of Isolated Organs Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Heart Perfusion Revenue Market Share by Player in 2024
Figure 19. Liver Perfusion Revenue Market Share by Player in 2024
Figure 20. Kidney Perfusion Revenue Market Share by Player in 2024
Figure 21. Lung Perfusion Revenue Market Share by Player in 2024
Figure 22. Global Normothermic Perfusion of Isolated Organs Revenue Market Share by Type (2020-2031)
Figure 23. Global Normothermic Perfusion of Isolated Organs Revenue Market Share by Application (2020-2031)
Figure 24. North America Normothermic Perfusion of Isolated Organs Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Normothermic Perfusion of Isolated Organs Revenue (US$ Million) in 2024
Figure 26. North America Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Normothermic Perfusion of Isolated Organs Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Normothermic Perfusion of Isolated Organs Revenue (US$ Million) in 2024
Figure 33. Europe Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 36. France Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Normothermic Perfusion of Isolated Organs Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Normothermic Perfusion of Isolated Organs Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 48. India Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Normothermic Perfusion of Isolated Organs Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Normothermic Perfusion of Isolated Organs Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Normothermic Perfusion of Isolated Organs Revenue (US$ Million) in 2024
Figure 56. Central and South America Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Normothermic Perfusion of Isolated Organs Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Normothermic Perfusion of Isolated Organs Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Normothermic Perfusion of Isolated Organs Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Normothermic Perfusion of Isolated Organs Revenue (US$ Million) in 2024
Figure 62. South America Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Normothermic Perfusion of Isolated Organs Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Normothermic Perfusion of Isolated Organs Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Normothermic Perfusion of Isolated Organs Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Normothermic Perfusion of Isolated Organs Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Normothermic Perfusion of Isolated Organs Revenue (2020-2025) & (US$ Million)
Figure 68. Normothermic Perfusion of Isolated Organs Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
